Cystic fibrosis. E84
Conditions
Interventions
Intervention group: participants received cyproheptadineTehran daro company (0.25 mg/kg, divided q12h) for six months.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were CF diagnosis confirmed via sweat test or genetic testing age 6–18 years and regardless of pancreatic insufficiency or disease severity.
Exclusion criteria
Exclusion criteria: known cyproheptadine allergy concurrent CNS depressant medication use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of weight gain. Timepoint: Before and after 6 months of use of cyproheptadin. Method of measurement: Scales for weight. | — |
Secondary
| Measure | Time frame |
|---|---|
| Height increase rate. Timepoint: Before and after 6 months of use of cyproheptadin. Method of measurement: meters for height.;Improve respiratory condition. Timepoint: Before and after 6 months of use of cyproheptadin. Method of measurement: Spirometery.;Quality of life. Timepoint: Before and after 6 months of use of cyproheptadin. Method of measurement: Quality of life questionnaire for cystic fibrosis patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh azizian
Esfahan University of Medical Sciences
Outcome results
None listed